Novato, CA, United States of America

Elena Fisheleva

USPTO Granted Patents = 1 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Elena Fisheleva in Treating Skeletal Dysplasia

Introduction

Elena Fisheleva is an accomplished inventor based in Novato, CA (US). She has made significant contributions to the field of medicine, particularly in the treatment of skeletal dysplasia in children. Her innovative work focuses on utilizing variants of C-type natriuretic peptide to improve growth outcomes in affected children.

Latest Patents

Elena holds 1 patent for her invention titled "C-type natriuretic peptide variants to treat skeletal dysplasia in children." This patent describes a method for treating skeletal dysplasias by administering variants of C-type natriuretic peptide (CNP). The treatment aims to enhance long bone growth and growth velocity, addressing critical symptoms associated with skeletal dysplasia.

Career Highlights

Elena is currently employed at BioMarin Pharmaceutical Inc., where she continues to develop her research and innovations. Her work has the potential to significantly impact the lives of children suffering from skeletal dysplasia, providing them with better growth outcomes and improved quality of life.

Collaborations

Elena collaborates with Jonathan Day, a fellow researcher, to further advance their understanding and treatment of skeletal dysplasia. Their partnership exemplifies the importance of teamwork in the field of medical research.

Conclusion

Elena Fisheleva's contributions to the treatment of skeletal dysplasia through her innovative patent demonstrate her commitment to improving children's health. Her work at BioMarin Pharmaceutical Inc. and collaboration with Jonathan Day highlight the collaborative nature of scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…